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smaller rise in serum [K1], 0.12 mEq/L above baseline (P 5ACE inhibition or angiotensin receptor blockade: Impact on
0.1), a 43% lower value when compared with the change inpotassium in renal failure.
those who received lisinopril. This blunted rise in [K1] in peopleBackground. Inhibition of the renin-angiotensin system is
taking valsartan was not associated with a significant decreaseknown to raise serum potassium [K1] levels in patients with
in plasma aldosterone (P 5 0.14).renal insufficiency or diabetes. No study has evaluated the
Conclusions. In the presence of renal insufficiency, the ARBcomparative effects of an angiotensin-converting enzyme
valsartan did not raise serum [K1] to the same degree as the(ACE) inhibitor versus an angiotensin receptor blocker (ARB)
ACE inhibitor lisinopril. This differential effect on serum [K1]on the changes in serum [K1] in people with renal insufficiency.
is related to a relatively smaller reduction in plasma aldoste-Methods. The study was a multicenter, randomized, double
rone by the ARB and is not related to changes in GFR. Thiscrossover design, with each period lasting one month. A total
study provides evidence that increases in serum [K1] are lessof 35 people (21 males and 14 females, 19 African Americans
likely with ARB therapy compared with ACE inhibitor therapyand 16 Caucasian) participated, with the mean age being 56 6
in people with renal insufficiency.2 years. Mean baseline serum [K1] was 4.4 6 0.1 mEq/L. The
glomerular filtration rate (GFR) was 65 6 5 mL/min/1.73 m2,
and blood pressure was 150 6 2/88 6 1 mm Hg. The main
outcome measure was the difference from baseline in the level
Drug-induced hyperkalemia, that is, serum potassiumof serum [K1], plasma aldosterone, and GFR following the
.5.5 mEq/L, is an important but often overlooked prob-initial and crossover periods.
Results. For the total group, serum [K1] changes were not lem encountered commonly in clinical practice. Medica-
significantly different between the lisinopril or valsartan treat- tions generally produce hyperkalemia either by causing
ments. The subgroup with GFR values of #60 mL/min/1.73 redistribution of potassium (b2-adrenergic blockers, suc-m2 who received lisinopril demonstrated significant increases
cinylcholine, digitalis overdose, hypertonic mannitol) orin serum [K1] of 0.28 mEq/L above the mean baseline of
by impairing renal potassium excretion. Drugs such as4.6 mEq/L (P 5 0.04). This increase in serum [K1] was also
accompanied by a decrease in plasma aldosterone (P 5 0.003). nonsteriodal anti-inflammatory drugs (NSAIDs), inhibi-
Relative to the total group, the change in serum [K1] from tors of the renin-angiotensin-aldosterone (RAA) system,
baseline to post-treatment in the lisinopril group was higher heparin, and cyclosporine impair renal potassium excre-
among those with GFR values of #60 mL/min/1.73 m2. The
tion by interfering with the production and/or secretionlower GFR group taking valsartan, however, demonstrated a
of aldosterone [1]. Renal insufficiency, defined by a glo-
merular filtration rate (GFR) of ,30 mL/min, is gener-
ally required to predispose someone to hyperkalemia1The VAL-K Study investigators (affiliations), in addition to the au-
thors of this article, include: Sarah Kasprowicz, Laura DeVivo, and [1]. Thus, an elevated serum potassium concentration in
Dinah White (Rush Presbyterian St. Luke’s Medical Center); Mitzi
a person with normal or mildly impaired renal functionThompson (University of Virginia at Charlottesville); Leena Hiremath,
and Diane Veley (Ohio State University Medical Center Laboratory); should not be attributed to renal insufficiency alone.
and Carment Merali (Cornell University Medical Center). One of the more common settings in which hyperka-
lemia appears to limit treatment of hypertension is inKey words: diabetes, kidney disease, plasma aldosterone, lisinopril,
valsartan, hyperkalemia. people who have pre-existing elevations of serum potas-
sium and/or renal insufficiency. Unfortunately, this fre-Received for publication March 14, 2000
quently necessitates discontinuation of angiotensin-con-and in revised form May 12, 2000
Accepted for publication May 19, 2000 verting enzyme (ACE) inhibitors in the people in whom
they have been shown to provide the greatest benefitÓ 2000 by the International Society of Nephrology
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with regard to slowing the progression of renal disease as serum potassium levels in people with hypertension
and varying degrees of renal insufficiency.[2]. In six separate clinical trials of more than 1500 people
with renal insufficiency, elevations in serum potassium
of between 0.3 and 0.6 mEq/L occurred in those random-
METHODS
ized to an ACE inhibitor [3–8]. This increase in serum
The participants were selected from screening throughpotassium necessitated discontinuation of the ACE in-
chart review of laboratory data, medical history, recenthibitor in between 1.2 and 1.6% of people in any given
physical exam findings, and current medical status. Eighty-trial.
four men and women were screened for the study, 37Further support for hyperkalemia limiting antihyper-
of whom met the inclusion and exclusion criteria. Thetensive therapy with ACE inhibitors in people with renal
inclusion criteria included the following: age between 18insufficiency stems from the results of a case-controlled
and 75 years, a serum potassium level between 4.3 andstudy of patients followed in a General Medicine Clinic
5.5 mEq/L, a history of hypertension, and a calculatedwith baseline serum potassium levels of greater than 5.1
creatinine clearance between 30 and 80 mL/min, as esti-mEq/L while on ACE inhibitor therapy [9]. Of 1818
mated by the Cockcroft and Gault equation and verifiedpatients reviewed, 194 (11%) developed further in-
by a 24-hour urine collection for creatinine clearance.creases in serum potassium when placed on ACE inhibi-
The exclusion criteria included unstable renal functiontor therapy. Moreover, 19% of the 11% (37 of 194) had
or active renal disease, patients who require diureticspotassium levels elevated to levels $5.6 mEq/L, with
for edema management, those who required three oronly 3 of the 194 (1.5%) reaching potassium levels of
more drugs to control blood pressure, a recent history$6 mEq/L. The most relevant factor for predicting hyp-
or evidence of drug or alcohol abuse, known allergieserkalemia in this study was a baseline serum creatinine
to ACE inhibitor, angiotensin II antagonists, or iodine,level of $1.6 mg/dL. It should be noted that in this study,
known positive for human immunodeficiency virus dis-as in clinical practice, the incidence of hyperkalemia was
ease (HIV), significant hepatic disease [serum glutamic-higher than appreciated in the more controlled setting
oxaloacetic transaniminase (SGOT) or serum glutamic-of the aforementioned clinical trials, thus making it a
pyruvic transaminase (SGPT) greater than three timesvery important and clinically relevant issue.
the upper limit of normal or total bilirubin or alkalineA separate dose–response study in people with chronic
phosphatase greater than 2.5], an average sitting bloodrenal insufficiency reported a low incidence of hyperka-
pressure of greater than 200/115 mm Hg, unstable anginalemia with angiotensin receptor blockers (ARBs) [10].
pectoris on treatment or history of a myocardial infarctionIn this study, no increase in serum potassium was noted
or coronary artery bypass surgery or angioplasty withinfollowing one month of treatment with low doses of the
three months of study entry, a history of a stroke withinARB losartan. However, an increase in serum potassium
three months of study entry, transient ischemic attack(0.3 mEq/L above baseline) did occur following an addi-
within six months of study entry, ventricular tachyarrhyth-tional month of therapy at the highest doses of the ARB.
mias requiring therapy, congestive heart failure, NYHAAdditional data to support potential differences between
Class II, III, or IV, pregnancy, lactation, or women ofACE inhibitors and ARBs on serum potassium concen-
childbearing potential, daily required use of intake of non-trations come from clinical trials that compare an ACE
steroidal anti-inflammatory agents, excluding aspirin, moreinhibitor to an ARB on renal function in people with
than 20 days per month (aspirin up to 325 mg/day washeart failure [11, 12]. These trials demonstrated a signifi-
permissible), and finally, a history of significant malab-cantly lower incidence of hyperkalemia (serum potas-
sorption or gastrointestinal surgery.sium $6 mEq/L) at one year in the more than 1000
Thirty five of the 37 participants (95%) completedpeople randomized to an ARB compared with those
the study. All of the individuals were scheduled for arandomized to the ACE inhibitor [11, 12].
screening visit. At this visit, all participants were givenTo date, there has been no clinical study that examines
an informed consent that was read to the participant andthe possible mechanisms to account for this differential
given to him/her in order to discuss the study participa-effect on serum potassium between ACE inhibitors and
tion with their primary health care provider. Addition-ARBs. The current study was designed to test the hy-
ally, a complete medical history and physical examina-pothesis that an ARB compared with ACE inhibitor fails
tion were completed as well as a review of the inclusion/to increase the serum potassium concentration signifi-
exclusion criteria. Participants were also informed aboutcantly in people with pre-existing renal insufficiency
salt substitutes and instructed to avoid all such sub-caused by a lesser effect on aldosterone production. To
stances during the study. Finally, they were instructedtest this hypothesis, a multicenter, randomized, crossover
and encouraged to follow a ,120 mEq/day sodium diet.design was implemented. The study assessed the effects
The individual then returned for the baseline examina-of an ARB and an ACE inhibitor on GFR, plasma aldo-
sterone, plasma renin activity, and angiotensin II, as well tion within two weeks. At this time, any questions regard-
Bakris et al: ACE inhibition and impact on potassium in renal failure2086
Fig. 1. Illustrated protocol of study. Mea-
surements of plasma renin, angiotensin II, al-
dosterone, serum [K1] 24-hour urine for so-
dium, potassium and aldosterone, and GFR
are by the iohexol method.
ing the study were addressed. All participants then urine specimens for potassium, sodium, and aldosterone
were collected in the 24-hour period immediately beforesigned the Institutional Review Board-approved consent
form and entered into the study. GFR determination. Methodology for these measure-
ments has also been previously described [14].The study implemented a randomized, crossover,
multicentered, open-label design that involved the ACE
Statistical analysesinhibitor lisinopril (10 mg/day) and the ARB valsartan
(80 mg/day). The illustrated protocol (Fig. 1) outlines This study was designed as an AB/BA crossover trial.
the study design and procedures carried out during the Each patient was treated with both lisinopril and valsar-
study. In brief, all participants had their antihypertensive tan, each for one month. However, patients were ran-
medication stopped. Those who had a diastolic blood domized to one of two groups, defined by whether lisino-
pressure above 115 mm Hg within the two-week washout pril was taken first [15]. The primary analysis involved
period were excluded from the study. The remaining a comparison of the average percentage change from
participants were randomized in a 1:1 fashion to either baseline in serum potassium levels between the two anti-
lisinopril 10 mg/day or valsartan 80 mg/day. Participants hypertensive drugs. Secondary analyses involved a com-
were maintained on this medication for one month, after parison of the average differences from baseline in the
which it was terminated, and a two-week washout period levels of plasma renin, angiotensin II, as well as urinary
ensued. Following the second washout period, individu- values of potassium, aldosterone, sodium, and others.
als were crossed over to the other medication and fol- Comparisons were made using the paired t-test, in
lowed for an additional period of one month. Follow- which the paired observation for each patient consisted
up visits from randomization to washout were conducted of the percentage change under lisinopril use and the
at the discretion of the investigator. Any serum potas- percentage change under valsartan. Sample size calcula-
sium value that was greater than or equal to 6.0 mEq/L tions were based on the primary analysis.
was considered a stop point. Participants were also Previous studies demonstrate that ACE inhibitors
dropped from the study if their systolic blood pressure generally raise serum potassium levels an average of
could not be reduced to less than 180 mm Hg or their 15% above baseline after a one-month period [2–9]. Con-
diastolic blood pressure to below 100 mm Hg while on versely, ARBs raise serum potassium levels an average
randomized drug. of 5% above baseline over the same period [10–12]. This
The GFR was measured using iohexol clearance at represents a 10% difference in the increase from baseline
the end of the washout periods and at the end of one between the two types of drugs. Thus, conservatively
month of therapy with each agent (Fig. 1). Thus, in total, assuming an overall standard deviation of 15 for the
four GFRs were performed on each participant over the percentage increase from baseline, a within-patient cor-
duration of the study. The methodology for these GFR relation of 0.20 between the percentage increase under
measurements has been previously described [13]. Dur- the ACE inhibitor and the ARB, and 80% power to
ing each of the GFR periods, plasma renin activity, an- detect a 10% point difference in the average percentage
increase between the two types of drug, 29 patients weregiotensin II levels, as well as plasma aldosterone activity
were also measured. Serum electrolytes such as potas- required [16]. Allowing an additional 15% for loss of
data, such as due to attrition, 35 patients were required.sium and sodium as well as bicarbonate were also mea-
sured during each of these periods. Twenty-four–hour Baseline characteristics were compared between the
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Table 1. Baseline and post-treatment values over all randomized participants, by drug
Variable Drug N Baseline Post-treatment P
Systolic blood pressure mm Hg L 35 15064 13965 0.002
V 35 14963 13965 0.002
Diastolic blood pressure mm Hg L 35 8562 8062 0.012
V 35 9062 8362 0.009
Glomerular filtration rate mL/min/1.73 m2 L 34 6264 6565 0.37
V 35 6665 6465 0.53
Serum potassium mEq/L L 34 4.4760.07 4.5960.10 0.19
V 35 4.4260.07 4.4260.11 0.94
Fractional excretion of potassium % L 33 17.562 19.863 0.61
V 35 20.063 21.662.6 0.53
Plasma renin activity ng/mL/hour L 34 1.6360.39 4.4261.55 0.06
V 35 1.8160.76 2.9460.56 0.19
Plasma angiotensin II pg/mL L 32 26.262.5 22.261.74 0.06
V 30 24.762.8 33.363.7 0.02
Plasma aldosterone pg/mL L 34 6.7360.65 4.9660.61 0.01
V 35 6.3160.62 5.260.65 0.07
Urinary aldosterone pg/mL L 33 4.560.48 3.7160.48 0.08
V 35 4.6760.52 4.3660.52 0.37
Data are expressed as mean 6 SE of the mean. P values reflect statistical comparison of mean values. Abbreviations are: L, lisinopril; V, valsartan.
two randomized groups using chi-square tests and Wil- monal characteristics of all randomized patients are
shown in Table 1. The primary analysis demonstratedcoxon signed-rank tests, as appropriate. Nonparametric
tests, such as Wilcoxon rank tests, were used any time no significant difference between the effect of lisinopril
or valsartan on serum potassium levels over all patientsthe relevant sample size was less than 30. Individual
effects of the two drugs were assessed by testing whether at the 0.05 level.
mean post-treatment values were significantly different
Individual and comparative drug effectsfrom mean pretreatment values using paired t-tests.
In comparing the effects between the two drugs onComparisons between the two drugs were made by com-
the other specified variables, only the mean change, fromparing mean post-treatment and pretreatment differ-
baseline, in plasma angiotensin II levels was significantlyences. Linear relationships between variables were ex-
different (P 5 0.005, Wilcoxon). The analyses proposedamined using multiple regression analyses. Because a
by Senn yielded similar results. The Senn analyses alsocrossover design was used, study data were also analyzed
showed no evidence of a carryover effect from the firstusing the methods of Senn, both as an alternative analysis
to the second drug.and to test the assumption of no carryover effect from
The changes in blood pressure, GFR, plasma renin,the first treatment to the second [15]. Finally, because
angiotensin II, plasma, and urinary aldosterone as wellrenal insufficiency can significantly influence many of
as serum and urinary potassium over all people studied,the metabolic and hemodynamic variables under study,
by drug, are shown in Table 1. A marginal increase inthese analyses were also performed stratified by low-
plasma renin activity (P 5 0.06), a marginal decrease inGFR status (baseline GFR #60 mL/min/1.73 m2) versus
plasma angiotensin II (P 5 0.06), and a significant de-high-GFR status (baseline GFR .60 mL/min/1.73 m2).
crease in plasma aldosterone (P 5 0.01) were noted withThese values were selected since they reflect a greater
lisinopril use. However, with valsartan use, the patientsthan 50% loss in renal function and clinically have been
experienced a significant increase in plasma angiotensinassociated with a higher probability for developing hyper-
II (P 5 0.02) and a lesser fall in plasma aldosterone (P 5kalemia [4, 9].
0.07).
RESULTS Analysis by level of renal function
Initial randomization To evaluate further the trends in hormone profiles
and serum potassium responses between the two agents,The mean 6 age of the participants was 56 6 2 years.
Of the 35 people who completed the study, 19 were we analyzed the groups based on level of renal function
at baseline. The baseline characteristics of those partici-African Americans, and 16 were Caucasian. Twenty-one
were males, and 14 were female. The group was obese pants stratified by level of GFR are shown in Table 2.
Those with baseline GFR values of #60 mL/min/1.73 m2with a body mass index of 31 6 1 kg/cm2 and a weight
of 91 6 4 kg. were significantly younger, more obese, and with higher
plasma levels of renin and angiotensin II but not aldoste-The baseline systemic, renal hemodynamic, and hor-
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Table 2. Baseline characteristics of the study participants based on GFR stratification demographic characteristics
, 60 mL/min/1.73 m2 . 60 mL/min/1.73 m2 P value
N 18 17
Age years 5263 6062 0.05
Race AA/C 7/11 12/5 NS
Sex M/F 11/7 10/7 NS
Weight kg 10167 8162 0.01
Body mass index kg/cm2 3461 2961 0.02
Metabolic and hemodynamic characteristics
Systolic blood pressure mm Hg 14664 15364 NS
Diastolic blood pressure mm Hg 8762 8962 NS
Serum creatinine mg/dL 1.660.1 1.160.1 ,0.0005
Glomerular filtration rate mL/min/1.73 m2 4362 8865 ,0.0005
Serum potassium mEq/L 4.660.1 4.360.1 0.04
Plasma renin activity ng/mL/hour 2.460.7 0.560.1 0.01
Plasma angiotensin II pg/mL 3164 2262 0.05
Plasma aldosterone pg/mL 6.360.8 7.161 NS
Values are expressed as mean 6 SE of the mean. Abbreviations are: AA, African American; C, Caucasian, M, Male; F, female.
Table 3. Metabolic and hemodynamic changes noted in the group with renal insufficiency (GFR ,60 mL/min)
Baseline Post Treatment
Valsartan Lisinopril Valsartan Lisinopril
Systolic blood pressure mm Hg 14664 14865 13863a 13964a
Diastolic blood pressure mm Hg 8762 8862 8362a 8462a
Serum creatinine mg/dL 1.660.1 1.560.1 1.660.1 1.560.1
Glomerular filtration rate mL/min/1.73 m2 4362 4262 4362 43 62
Serum potassium mEq/L 4.560.1 4.660.1 4.660.2 4.960.1a
Plasma renin activity ng/mL/hour 361.4 360.7 1163.9a 763a
Plasma angiotensin II pg/mL 3065 3165 3966 2364a
Plasma aldosterone pg/mL 5.960.8 6.860.7 4.460.6 3.660.4a
Values are expressed as mean 6 SE of the mean.
a P , 0.05 compared to respective baseline value
rone (Table 2). They also had modestly higher mean randomized to lisinopril (23.2 6 0.9 Dpg/mL, lisinopril
vs. 21.1 6 0.8 Dpg/mL, valsartan, P , 0.003). Thesebaseline serum potassium levels when compared with
the higher GFR group (Table 2). The mean change in differential effects on plasma aldosterone and serum po-
tassium between these two inhibitors of the RAA systemGFR in both groups was not significantly changed from
baseline. In the low GFR group, the difference between could not be explained by differences in blood pressure
or GFR (Fig. 4). Importantly, these relationships betweenthe two agents was clearly not significant (1 6 2 DmL/
min/1.73 m2, lisinopril vs. 1 6 2 DmL/min/1.73 m2, valsar- plasma aldosterone and serum potassium were present
regardless of which agent was given first. This furthertan, P . 0.5).
In people with a baseline GFR of #60 mL/min/1.73 supports the notion that the washout process was effec-
tive.m2, lisinopril significantly increased serum potassium lev-
els (P 5 0.047) as well as plasma renin activity (Table Among the people whose baseline GFR was .60 mL/
min/1.73 m2, both lisinopril (P 5 0.004) and valsartan3). It decreased plasma angiotensin II and plasma aldo-
sterone compared with the change in people with better (P 5 0.002) significantly increased plasma renin activity,
while only valsartan significantly increased plasma angio-renal function (Fig. 2). Moreover, in this low GFR group,
the correlation between plasma aldosterone and serum tensin II (P 5 0.04). All P values reported above in this
subsection are based on the use of Wilcoxon signed-rankpotassium was higher with the ACE inhibitor than with
the ARB (Fig. 3). Note also that while valsartan, like tests.
Regression analyses showed that the change in serumlisinopril, significantly increased plasma renin activity, it
only marginally increased plasma angiotensin II levels potassium from baseline to post-treatment with lisinopril
was significantly correlated with the same change in(Table 3). This marginal increase in angiotensin II levels
in the valsartan group corresponded to a blunted reduc- plasma aldosterone. This correlation was even higher
among those with GFR values at or below 60 mL/min/tion in plasma aldosterone levels (P 5 0.21). This change
in plasma aldosterone levels was more marked in those 1.73 m2 (Fig. 3). A similar correlation, however, was not
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Fig. 2. Comparative effects of lisinopril and
valsartan on changes in serum potassium and
plasma aldosterone in people with two differ-
ent levels of renal function (A and B). *P ,
0.05 compared with baseline value.
Fig. 3. Association between changes in se-
rum potassium as a function of change in
plasma aldosterone in people with two differ-
ent levels of renal function: (A) GFR # 60
mL/min/1.73 m2 (r 5 0.35 lisinopril, r 5 0.14
valsartan), and (B) GFR . 60 mL/min/1.73 m2
(r 5 0.43 lisinopril, r 5 0.33 valsartan). *P ,
0.02 compared with valsartan for those with
GFR , mL/min/1.73 m2. Symbols are: (j)
lisinopril; (r) valsartan.
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Fig. 4. Association between the change in se-
rum potassium as a function of change in glo-
merular filtration rate in people with two dif-
ferent levels of renal function: (A) GFR # 60
mL/min/1.73 m2 (r 5 0.12 lisinopril, r 5 0.05
valsartan; P 5 0.12), and (B) GFR . 60 mL/
min/1.73 m2 (r 5 0.12 lisinopril, r 5 0.41 valsar-
tan; P 5 0.16). Symbols are: (j) lisinopril; (r)
valsartan.
observed in those with comparable GFR values treated volunteers [18]. This latter observation was also observed
with valsartan (Fig. 3). in 25 normotensive people with normal renal function
placed on a low-sodium diet [19]. This latter study, how-
ever, noted a relatively greater aldosterone reduction byDISCUSSION
the ACE inhibitor compared to the ARB [19]. Our study
The results of this trial demonstrate that there is a participants were not placed on a sodium-restricted diet.
clear difference in the degree of serum potassium in- They were instructed, however, to ingest ,150 mEq/L
crease from baseline between the ACE inhibitor and of sodium per day. Sodium intake for the group ranged
ARB studied in those with a GFR below 60 mL/min/ from 120 to 215 mEq/day at the end of each crossover
1.73 m2. Specifically, the ACE inhibitor lisinopril signifi- period, with no differences between those taking either
cantly increased the serum potassium concentration from agent. These data are consistent with those placed on
a baseline of 4.6 mEq/L to levels between 4.9 and 5.3 non–sodium-restricted diets.
mEq/L at study end. This is compared with the ARB Conversely, clinical trials in people with moderate to
valsartan that increased potassium from 4.6 mEq/L at severe renal insufficiency have noted differences in the
baseline to levels between 4.6 and 4.8 mEq/L at study incidence of hyperkalemia between these two drug
end. The degree of serum potassium rise correlated with
classes [2, 9–12]. To our knowledge, however, this is the
the degree of aldosterone reduction. A significant reduc-
first multicentered study that compares the effects oftion in plasma aldosterone was noted in those taking
these two classes of agents in the same patients withlisinopril and was independent of blood pressure reduc-
variable degrees of renal insufficiency. Taken togethertion, baseline serum potassium, or change in GFR. The
with previous studies, these data support the conceptmagnitude of aldosterone reduction was much less in
that ARBs reduce the risk of hyperkalemia in people atthose who received the ARB.
high risk for such an event compared with ACE inhibi-While studies have been performed in normal subjects
tion.to compare the effects of an ARB with an ACE inhibitor
Several possible reasons could account for the ob-on changes in the renin-angiotensin system and serum
served differences in degree of potassium elevation be-potassium, no studies have been carried out in people
tween these two agents. One potential explanation iswith moderate to severe renal insufficiency to evaluate
that the group with a lower GFR had a higher baselinethe relative differences between these agents in the con-
potassium level, a factor known to increase plasma aldo-text of changes in the renin-angiotensin system. Patient-
sterone levels. Serum potassium elevation above its nor-oriented, clinical studies confirm our observation of no
mal range, that is, .5.5 mEq/L, enhances the kaliureticsubstantive reductions in aldosterone with an ARB or
action of aldosterone [20]. However, there were no dif-ACE inhibitor in people with relatively normal renal
ferences in baseline plasma aldosterone levels betweenfunction. Goldberg et al compared the chronic effects
the two groups, thus making this an unlikely explanationof an ARB to an ACE inhibitor in normal subjects and
to account for the differences in potassium response.found no difference in the aldosterone effect [17]. Other
Moreover, only 3 of our 35 (8.5%) participants achievedinvestigators, however, have described a low-sodium de-
pendency of an ARB to reduce aldosterone in normal this level of serum potassium. Thus, the meaningfulness
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of this aforementioned mechanism to account for the prostaglandin levels [27]. Gomez-Martino et al examined
the contribution of prostaglandins in diabetic patientsdifference between these agents is not testable.
Another important reason for this difference in serum with renal insufficiency on potassium excretion. Much
like our low GFR group, participants in this study hadpotassium elevation may relate to a blunted stimulation
by angiotensin II of aldosterone in older people who an average GFR of 34 mL/min. Prostaglandin adminis-
have lost a certain amount of renal function. While there tration significantly increased plasma potassium when
are no data to support a blunted role of angiotensin II compared with controls and plasma aldosterone de-
stimulation on aldosterone production in such individu- creased. This effect of prostaglandins on neurohumoral
als, there are data to support reduced levels of aldoste- systems has also been described in heart failure [28].
rone and a blunted response to increased potassium. While we did not measure prostaglandins in our study,
Earlier studies in people with renal insufficiency support it is well established that ACE inhibitors increase prosta-
the concept of lower baseline levels of plasma aldoste- glandins of the E series and prostacyclin; this has not
rone as well as a blunted response in potassium excretion yet been demonstrated for ARBs [28, 29].
to aldosterone loading [21]. More recently, studies by
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